While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them ...

Semaglutide is the active ingredient in Novo Nordisk's weight loss drug Wegovy and diabetes counterpart Ozempic, and tirzepatide is the active ingredient in Lilly's obesity injection Zepbound and ...